Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 09 November 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) on Thursday released a draft guidance for consultation on a revision to the International Council for Harmonization (ICH) guideline on reproductive toxicity testing.
The draft ICH guideline, S5(R3) Detection of Toxicity to Reproduction for Human Pharmaceuticals, was endorsed by the ICH Assembly in August and is currently in Step 3 of the formal ICH procedure as participating regulators hold public consultations on the guideline.
Specifically, the draft guideline discusses considerations for drugmakers when developing a testing strategy for identifying and characterizing the reproductive risk posed by a drug.
The guideline says that drugmakers should generally provide data from adult animals exposed to a drug and assess the drug's impact on "all stages of development from conception to sexual maturity."
But the guideline notes that "flexibility in testing strategy is warranted" as it is impossible to cover all possible scenarios in a single guideline.
That said, the guideline says that drugmakers should consider the following key factors when developing their reproductive toxicity testing strategy:
According to FDA, the revised guideline is "intended to align with other ICH guidances, elaborate on concepts to consider when designing studies, and identify potential circumstances in which a risk assessment can be made based on preliminary studies."
FDA also says the draft guideline includes additional clarifications on the qualification and potential use of alternative assays to test for reproductive toxicity.
"To support using alternative assays, compounds that are either positive or negative in their ability to induce embryolethality or malformations are used in the process of qualifying assays," FDA writes.
But as FDA notes in the Federal Register notice announcing the consultation, the list of compounds identified in the draft guideline is not complete, and as such the agency says it is specifically looking for comments on additional compounds that could be added.
FDA, Federal Register Notice
Tags: Reproductive Toxicity, ICH, S5(R3), Draft Guideline
Regulatory Focus newsletters
All the biggest regulatory news and happenings.